AIM:SUN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Surgical Innovations Group

Executive Summary

Surgical Innovations Group plc designs, develops, manufactures, and sells devices for use in minimally invasive surgery (SI) and precision engineering markets in the United Kingdom, Europe, the Asia Pacific, the United States, and internationally. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Surgical Innovations Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SUN is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: SUN's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

7.1%

SUN

-1.0%

GB Medical Equipment

-0.3%

GB Market


1 Year Return

-33.3%

SUN

-11.5%

GB Medical Equipment

-11.0%

GB Market

Return vs Industry: SUN underperformed the UK Medical Equipment industry which returned -11.7% over the past year.

Return vs Market: SUN underperformed the UK Market which returned -10% over the past year.


Shareholder returns

SUNIndustryMarket
7 Day7.1%-1.0%-0.3%
30 Day-3.2%1.8%10.2%
90 Day-21.9%-3.1%6.4%
1 Year-33.3%-33.3%-9.7%-11.5%-7.4%-11.0%
3 Year-54.9%-54.9%15.4%8.7%0.9%-11.5%
5 Year-9.1%-9.1%35.1%24.1%26.5%-2.5%

Long-Term Price Volatility Vs. Market

How volatile is Surgical Innovations Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Surgical Innovations Group undervalued compared to its fair value and its price relative to the market?

1.23x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: SUN (£0.02) is trading above our estimate of fair value (£0)

Significantly Below Fair Value: SUN is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: SUN is unprofitable, so we can't compare its PE Ratio to the GB Medical Equipment industry average.

PE vs Market: SUN is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SUN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SUN is good value based on its PB Ratio (1.2x) compared to the GB Medical Equipment industry average (3.5x).


Next Steps

Future Growth

How is Surgical Innovations Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

25.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Surgical Innovations Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Surgical Innovations Group performed over the past 5 years?

14.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SUN is currently unprofitable.

Growing Profit Margin: SUN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SUN is unprofitable, but has reduced losses over the past 5 years at a rate of 14.1% per year.

Accelerating Growth: Unable to compare SUN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SUN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-36.8%).


Return on Equity

High ROE: SUN has a negative Return on Equity (-50.3%), as it is currently unprofitable.


Next Steps

Financial Health

How is Surgical Innovations Group's financial position?


Financial Position Analysis

Short Term Liabilities: SUN's short term assets (£6.9M) exceed its short term liabilities (£1.9M).

Long Term Liabilities: SUN's short term assets (£6.9M) exceed its long term liabilities (£3.2M).


Debt to Equity History and Analysis

Debt Level: SUN's debt to equity ratio (23.2%) is considered satisfactory.

Reducing Debt: SUN's debt to equity ratio has reduced from 98% to 23.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable SUN has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: SUN is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 22.1% per year.


Next Steps

Dividend

What is Surgical Innovations Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SUN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SUN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SUN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SUN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SUN's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

David Marsh

1.75yrs

Tenure

UK£186,000

Compensation

Mr. David John Marsh has been the Chief Executive Officer of Surgical Innovations Group plc since February 28, 2019. Mr. Marsh served as Group Commercial Director at Surgical Innovations Group plc on the a...


CEO Compensation Analysis

Compensation vs Market: David's total compensation ($USD247.98K) is about average for companies of similar size in the UK market ($USD345.93K).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
David Marsh
CEO & Director1.75yrsUK£186.00k3.35%
£ 468.7k
Adam Power
Group Development Director & Director3.25yrsUK£165.00k3.36%
£ 469.6k
Charmaine Day
CFO, Group Financial Controller & Company Secretary1.33yrsno data0.086%
£ 12.1k
Alex Hogg
Operations Director1.67yrsno datano data

1.7yrs

Average Tenure

Experienced Management: SUN's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
David Marsh
CEO & Director1.75yrsUK£186.00k3.35%
£ 468.7k
Adam Power
Group Development Director & Director3.25yrsUK£165.00k3.36%
£ 469.6k
Nigel Rogers
Independent Non-Executive Chairman5.08yrsUK£49.00k0.71%
£ 99.2k
Alistair Taylor
Independent Non-Executive Director4.83yrsUK£20.00k0.12%
£ 16.1k
Michael McMahon
Non-Executive Clinical Director & Member of Clinical Advisory Boardno dataUK£20.00k2%
£ 280.0k
Ian Brayshaw
Member of the Clinical Advisory Boardno datano datano data
Philippe Grange
Member of the Clinical Advisory Boardno datano datano data
Marco Adamo
Member of the Clinical Advisory Board9.83yrsno datano data
James Halstead
Member of the Clinical Advisory Board8.83yrsno datano data
Chris Sutton
Member of the Clinical Advisory Board8.83yrsno datano data
John Griffith
Member of the Clinical Advisory Board7.92yrsno datano data
Paul Hardy
Independent Non-Executive Director4.83yrsUK£20.00k0.76%
£ 106.6k

5.1yrs

Average Tenure

68.5yo

Average Age

Experienced Board: SUN's board of directors are considered experienced (5.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.3%.


Top Shareholders

Company Information

Surgical Innovations Group plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Surgical Innovations Group plc
  • Ticker: SUN
  • Exchange: AIM
  • Founded: 1992
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: UK£13.992m
  • Shares outstanding: 932.82m
  • Website: https://www.sigroupplc.com

Number of Employees


Location

  • Surgical Innovations Group plc
  • Clayton Wood House
  • 6 Clayton Wood Bank
  • Leeds
  • West Yorkshire
  • LS16 6QZ
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SUNAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPJan 1992

Biography

Surgical Innovations Group plc designs, develops, manufactures, and sells devices for use in minimally invasive surgery (SI) and precision engineering markets in the United Kingdom, Europe, the Asia Pacifi...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/26 19:25
End of Day Share Price2020/11/26 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.